Uncategorized

Direct Biologics Reports Compelling Data as ExoFlo ™ Expanded Access Program in Hospitalized COVID-19 Patients with Moderate-to-Severe ARDS Surpasses 100 Subjects.

Nano Labs Ltd announced today that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) on April 18, 2023.

MacuHealth, the leader in innovative eye supplements, is introducing LifeMeter, a portable, non-invasive device proven to measure the presence of vital antioxidants known as carotenoids.

Noticias de la actualidad científica y tecnológica del 14 de abril de 2023.     …

Virax Biolabs Group Limited announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.

Zucara Therapeutics Inc., today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for ZT-01 for the prevention of night-time (nocturnal) hypoglycemia in patients with Type 1 Diabetes (“T1D”).

Palatin Technologies today announced preliminary fiscal third quarter ended March 31, 2023 Vyleesi® product revenue results.

Annovis Bio, Inc. today announced that patient recruitment for the Company’s Phase 2/3 study of buntanetap for the treatment of moderate Alzheimer’s disease (AD) remains consistent with its planned development program.

AlzeCure Pharma AB announced that an abstract on ACD440, the leading non-opioid drug candidate in the Painless platform, has been accepted for presentation at the annual international pain conference EFIC, European Pain Federation, which this year is being held in Budapest, Hungary, on September 20-22.

Lytix Biopharma AS, a clinical stage immuno-oncology company, announces the election of a new Chairman of the Board at ‘s General Assembly.